心肌梗塞时血栓形成的规律已经得到充分证实,有证据表明血小板在血栓形成过程中起着关键作用。阿司匹林即使应用很低的剂量,对血小板聚集作用也有显著的影响。因此,阿司匹林在心血管和其他情况的抗血栓效果是令人关注的继发预防研究。对至少患过一次心肌梗塞的病人使用阿司匹林来预防心肌梗塞和/或死亡方面曾进行六次大规模的双盲法随机的对照试验。其中五次试验的结果表明全部测定结果的发生率明显地相似。然而另一次试验的结果稍有不同,当时虽然阿司匹林确实能够降低病人非致命心肌梗塞的发生率,但对病人的死亡率并无明显降低。在所有六次试验中死亡率的趋向在统计学上来说是相似的;因此把所有这些试验结果分隔出来是没有理由的。如果试验结果综合起 The pattern of thrombosis in myocardial infarction has been well documented and there is evidence that platelets play a key role in thrombosis. Aspirin has a significant effect on platelet aggregation even at very low doses. As a result, the antithrombotic effect of aspirin in cardiovascular and other settings is a secondary secondary prevention study. Six large, double-blind, randomized, controlled trials of aspirin in preventing myocardial infarction and / or death in patients with at least one myocardial infarction were performed. The results of five trials showed that the incidence of all the test results was significantly similar. However, the results of the other trial were slightly different. Although aspirin did reduce the incidence of nonfatal myocardial infarction at the time, there was no significant reduction in patient mortality. The trend in mortality rates in all six trials is statistically similar; therefore, it is not justified to separate all these test results. If the test results combined